FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1574663134> ?p ?o ?g. }

• W1574663134 endingPage "10" @default.
• W1574663134 startingPage "10" @default.
• W1574663134 abstract "BACKGROUND: DC derived-exosomes are nanomeric vesicles harboring functional MHC/peptide complexes capable of promoting T cell immune responses and tumor rejection. Here we report the feasability and safety of the first Phase I clinical trial using autologous exosomes pulsed with MAGE 3 peptides for the immunization of stage III/IV melanoma patients. Secondary endpoints were the monitoring of T cell responses and the clinical outcome. PATIENTS AND METHODS: Exosomes were purified from day 7 autologous monocyte derived-DC cultures. Fifteen patients fullfilling the inclusion criteria (stage IIIB and IV, HLA-A1+, or -B35+ and HLA-DPO4+ leukocyte phenotype, tumor expressing MAGE3 antigen) were enrolled from 2000 to 2002 and received four exosome vaccinations. Two dose levels of either MHC class II molecules (0.13 versus 0.40 x 1014 molecules) or peptides (10 versus 100 mug/ml) were tested. Evaluations were performed before and 2 weeks after immunization. A continuation treatment was performed in 4 cases of non progression. RESULTS: The GMP process allowed to harvest about 5 x 1014 exosomal MHC class II molecules allowing inclusion of all 15 patients. There was no grade II toxicity and the maximal tolerated dose was not achieved. One patient exhibited a partial response according to the RECIST criteria. This HLA-B35+/A2+ patient vaccinated with A1/B35 defined CTL epitopes developed halo of depigmentation around naevi, a MART1-specific HLA-A2 restricted T cell response in the tumor bed associated with progressive loss of HLA-A2 and HLA-BC molecules on tumor cells during therapy with exosomes. In addition, one minor, two stable and one mixed responses were observed in skin and lymph node sites. MAGE3 specific CD4+ and CD8+ T cell responses could not be detected in peripheral blood. CONCLUSION: The first exosome Phase I trial highlighted the feasibility of large scale exosome production and the safety of exosome administration." @default.
• W1574663134 created "2016-06-24" @default.
• W1574663134 creator A5000473619 @default.
• W1574663134 creator A5001814176 @default.
• W1574663134 creator A5002072156 @default.
• W1574663134 creator A5002659299 @default.
• W1574663134 creator A5011516091 @default.
• W1574663134 creator A5021766914 @default.
• W1574663134 creator A5022288769 @default.
• W1574663134 creator A5028436035 @default.
• W1574663134 creator A5031362151 @default.
• W1574663134 creator A5037427764 @default.
• W1574663134 creator A5042162371 @default.
• W1574663134 creator A5044244232 @default.
• W1574663134 creator A5045036248 @default.
• W1574663134 creator A5045823942 @default.
• W1574663134 creator A5049672639 @default.
• W1574663134 creator A5056132643 @default.
• W1574663134 creator A5057520239 @default.
• W1574663134 creator A5058336995 @default.
• W1574663134 creator A5066882928 @default.
• W1574663134 creator A5068413883 @default.
• W1574663134 creator A5074612242 @default.
• W1574663134 creator A5075990267 @default.
• W1574663134 creator A5079778350 @default.
• W1574663134 creator A5087980869 @default.
• W1574663134 date "2005-01-01" @default.
• W1574663134 modified "2023-10-18" @default.
• W1574663134 cites W1493538138 @default.
• W1574663134 cites W1515157281 @default.
• W1574663134 cites W1542448731 @default.
• W1574663134 cites W1574076960 @default.
• W1574663134 cites W1762620449 @default.
• W1574663134 cites W1804501722 @default.
• W1574663134 cites W1838162521 @default.
• W1574663134 cites W1874379912 @default.
• W1574663134 cites W1889489351 @default.
• W1574663134 cites W1965998502 @default.
• W1574663134 cites W1977812921 @default.
• W1574663134 cites W1984455978 @default.
• W1574663134 cites W2000749507 @default.
• W1574663134 cites W2013603806 @default.
• W1574663134 cites W2022567163 @default.
• W1574663134 cites W2026763255 @default.
• W1574663134 cites W2027351381 @default.
• W1574663134 cites W2028248159 @default.
• W1574663134 cites W2033598310 @default.
• W1574663134 cites W2041302454 @default.
• W1574663134 cites W2076730875 @default.
• W1574663134 cites W2080879611 @default.
• W1574663134 cites W2095825164 @default.
• W1574663134 cites W2099515509 @default.
• W1574663134 cites W2134881264 @default.
• W1574663134 cites W2142501626 @default.
• W1574663134 cites W2146541911 @default.
• W1574663134 cites W2155366992 @default.
• W1574663134 cites W2159597545 @default.
• W1574663134 cites W2161343890 @default.
• W1574663134 cites W2165951569 @default.
• W1574663134 cites W2168622467 @default.
• W1574663134 doi "https://doi.org/10.1186/1479-5876-3-10" @default.
• W1574663134 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/554765" @default.
• W1574663134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15740633" @default.
• W1574663134 hasPublicationYear "2005" @default.
• W1574663134 type Work @default.
• W1574663134 sameAs 1574663134 @default.
• W1574663134 citedByCount "971" @default.
• W1574663134 countsByYear W15746631342012 @default.
• W1574663134 countsByYear W15746631342013 @default.
• W1574663134 countsByYear W15746631342014 @default.
• W1574663134 countsByYear W15746631342015 @default.
• W1574663134 countsByYear W15746631342016 @default.
• W1574663134 countsByYear W15746631342017 @default.
• W1574663134 countsByYear W15746631342018 @default.
• W1574663134 countsByYear W15746631342019 @default.
• W1574663134 countsByYear W15746631342020 @default.
• W1574663134 countsByYear W15746631342021 @default.
• W1574663134 countsByYear W15746631342022 @default.
• W1574663134 countsByYear W15746631342023 @default.
• W1574663134 crossrefType "journal-article" @default.
• W1574663134 hasAuthorship W1574663134A5000473619 @default.
• W1574663134 hasAuthorship W1574663134A5001814176 @default.
• W1574663134 hasAuthorship W1574663134A5002072156 @default.
• W1574663134 hasAuthorship W1574663134A5002659299 @default.
• W1574663134 hasAuthorship W1574663134A5011516091 @default.
• W1574663134 hasAuthorship W1574663134A5021766914 @default.
• W1574663134 hasAuthorship W1574663134A5022288769 @default.
• W1574663134 hasAuthorship W1574663134A5028436035 @default.
• W1574663134 hasAuthorship W1574663134A5031362151 @default.
• W1574663134 hasAuthorship W1574663134A5037427764 @default.
• W1574663134 hasAuthorship W1574663134A5042162371 @default.
• W1574663134 hasAuthorship W1574663134A5044244232 @default.
• W1574663134 hasAuthorship W1574663134A5045036248 @default.
• W1574663134 hasAuthorship W1574663134A5045823942 @default.
• W1574663134 hasAuthorship W1574663134A5049672639 @default.
• W1574663134 hasAuthorship W1574663134A5056132643 @default.
• W1574663134 hasAuthorship W1574663134A5057520239 @default.
• W1574663134 hasAuthorship W1574663134A5058336995 @default.

• next